Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
Nathan Simon1, David FitzGerald2
1Biotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 37/5124 Bethesda, MD 20892, USA. nathan.simon@nih.gov.
Abstract:
Many epithelial cancers rely on enhanced expression of the epidermal growth factor receptor (EGFR) to drive proliferation and survival pathways. Development of therapeutics to target EGFR signaling has been of high importance, and multiple examples have been approved for human use. However, many of the current small molecule or antibody-based therapeutics are of limited effectiveness due to the inevitable development of resistance and toxicity to normal tissues. Recombinant immunotoxins are therapeutic molecules consisting of an antibody or receptor ligand joined to a protein cytotoxin, combining the specific targeting of a cancer-expressed receptor with the potent cell killing of cytotoxic enzymes. Over the decades, many bacterial- or plant-based immunotoxins have been developed with the goal of targeting the broad range of cancers reliant upon EGFR overexpression. Many examples demonstrate excellent anti-cancer properties in preclinical development, and several EGFR-targeted immunotoxins have progressed to human trials. This review summarizes much of the past and current work in the development of immunotoxins for targeting EGFR-driven cancers.
Insights
Recombinant immunotoxins offer a promising strategy for targeting cancers driven by epidermal growth factor receptor (EGFR) overexpression. This approach combines specific cancer cell targeting with potent cytotoxic effects, overcoming limitations of current therapies.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Epithelial cancers frequently overexpress the epidermal growth factor receptor (EGFR), driving tumor growth and survival.
- Current EGFR-targeting therapeutics (small molecules, antibodies) face challenges with resistance and off-target toxicity.
- Recombinant immunotoxins merge specific receptor targeting with potent cytotoxic payloads for cancer therapy.
Purpose of the Study:
- To review the development and application of recombinant immunotoxins targeting EGFR-overexpressing cancers.
- To highlight the potential of immunotoxins in overcoming resistance and toxicity associated with conventional EGFR therapies.
Main Methods:
- Literature review of preclinical and clinical studies on EGFR-targeted immunotoxins.
- Analysis of immunotoxin design, including antibody/ligand selection and cytotoxic payloads.
- Evaluation of efficacy and safety data from various EGFR-targeting immunotoxin development programs.
Main Results:
- Numerous EGFR-targeted immunotoxins have demonstrated significant anti-cancer activity in preclinical models.
- Several immunotoxin candidates have advanced to human clinical trials for EGFR-driven malignancies.
- Bacterial and plant-based toxins have been successfully employed as cytotoxic components.
Conclusions:
- Recombinant immunotoxins represent a viable and evolving therapeutic strategy for EGFR-driven cancers.
- Further development and clinical investigation of EGFR-targeted immunotoxins are warranted to improve patient outcomes.
- Immunotoxins offer a potential solution to overcome resistance and reduce toxicity in EGFR-targeted cancer therapy.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Related Concept Videos
01:27Tumor Immunotherapy
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...